# Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Study · id `cardio:ct-nct02226003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02226003](<https://clinicaltrials.gov/study/NCT02226003>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02226003

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.

## Technical summary

Registry record NCT02226003. Randomized; double masking; primary purpose treatment. Start 2014-09-23 (actual); primary completion 2016-02-23 (actual). Results posted on 2017-04-07.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 291 participants (enrolled count; ClinicalTrials.gov record NCT02226003, source copy `cardio:ctgov-nct02226003-2018-09-13`, retrieved 2026-10-26)
- Started: 2014-09-23 (actual) (ClinicalTrials.gov record NCT02226003, source copy `cardio:ctgov-nct02226003-2018-09-13`, retrieved 2026-10-26)
- Primary completion: 2016-02-23 (actual) (ClinicalTrials.gov record NCT02226003, source copy `cardio:ctgov-nct02226003-2018-09-13`, retrieved 2026-10-26)
- Completion: 2016-02-23 (actual) (ClinicalTrials.gov record NCT02226003, source copy `cardio:ctgov-nct02226003-2018-09-13`, retrieved 2026-10-26)
- Results first posted: 2017-04-07 (ClinicalTrials.gov record NCT02226003, source copy `cardio:ctgov-nct02226003-2018-09-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02226003-2018-09-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ertugliflozin
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Placebo to Ertugliflozin
- Intervention (Drug): Placebo to Sitagliptin
- Intervention (Drug): Glimepiride
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 2fe9e550d64165a49e317fcb4c4032c46ab03e92384b4e28695265aa416be4dc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
